Revelation Biosciences, Inc. financial data

Symbol
REVB, REVBW on Nasdaq
Industry
Pharmaceutical Preparations
Location
4660 Lajolla Village Drive, Suite 100, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Petra Acquisition Inc. (to 1/11/2022)
Latest financial report
10-Q - Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 273 % +84.2%
Debt-to-equity 57.3 % -71.4%
Return On Assets -62.7 % -377%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.63 M shares -63.8%
Common Stock, Shares, Outstanding 1.63 M shares -65.5%
Entity Public Float 7.31 M USD -45%
Common Stock, Value, Issued 1.63 K USD -65.5%
Weighted Average Number of Shares Outstanding, Basic 1.09 M shares +705%
Weighted Average Number of Shares Outstanding, Diluted 1.09 M shares +556%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.34 M USD +95.2%
General and Administrative Expense 4.6 M USD +25.2%
Operating Income (Loss) -8.94 M USD -51.6%
Nonoperating Income (Expense) -21.9 K USD -100%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -8.96 M USD -560%
Earnings Per Share, Basic -48.5 USD/shares +44.7%
Earnings Per Share, Diluted -40.1 USD/shares +58.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.6 M USD -17.8%
Assets, Current 14.6 M USD -18.9%
Property, Plant and Equipment, Net 78 K USD -7.01%
Assets 14.7 M USD -18.9%
Accounts Payable, Current 1.68 M USD +139%
Accrued Liabilities, Current 620 K USD -36.3%
Liabilities, Current 5.23 M USD -35.5%
Liabilities 5.23 M USD -35.5%
Retained Earnings (Accumulated Deficit) -28.1 M USD -46.7%
Stockholders' Equity Attributable to Parent 9.47 M USD -5.44%
Liabilities and Equity 14.7 M USD -18.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.84 M USD -80.2%
Net Cash Provided by (Used in) Financing Activities 5.42 M USD -61.4%
Net Cash Provided by (Used in) Investing Activities -19.2 K USD
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 1.63 M shares -65.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.6 M USD -17.8%
Deferred Tax Assets, Valuation Allowance 10.5 M USD +23.6%
Deferred Tax Assets, Gross 10.5 M USD +23.6%
Depreciation 25 K USD 0%
Payments to Acquire Property, Plant, and Equipment 19.2 K USD
Property, Plant and Equipment, Gross 151 K USD +14.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.28 M USD +32.1%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 37.6 M USD +28.8%
Share-based Payment Arrangement, Expense 156 K USD -20.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%